Automated systems and methods for analysis of protein post-translational modification

• US 20030153007A1
• Filed: 12/26/2002
• Published: 08/14/2003
• Est. Priority Date: 12/28/2001
• Status: Abandoned Application

• Current Assignee: Protana, Inc.
• Original Assignee: Protana, Inc.
• Inventors: Chen, Jian, Daniel Figeys, Joseph Michel, Larsen, Brett, White, Forest M.
• Application Number:
  US10/330,861
• Publication Number:
  US 20030153007A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: G01N 33/6803 General methods of protein analysis not limited to specific proteins or families of proteins
• CPC Class Codes: G01N 33/6812 Assays for specific amino acids
• CPC Class Codes: G01N 33/6818 Sequencing of polypeptides
• CPC Class Codes: G01N 33/6821 involving C-terminal degradation
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry

Abstract

Methods and systems of applying mass spectrometry to the analysis of peptides and amino acids, especially in the proteome setting. More particularly, the invention relates to a mass spectrometry-based method for detection of amino acid modifications, such as phosphorylation.

Claims

1. An automated method for identifying modified amino acids within a protein, comprising:

(i) providing one or more protein samples and an affinity capture reagent for isolating, from the protein samples, those proteins which have been post-translationally modified with a moiety of interest;

(ii) processing the protein samples to chemically modify at least one of the C-terminal carboxyl, the N-terminal amine and amino acid side chains of proteins in the protein samples so as to increase the specificity of the affinity capture reagent for those proteins which have been post-translationally modified with the moiety of interest;

(iii) isolating proteins post-translationally with the moiety of interest from the proteins samples using the affinity capture reagent; and

,

(iv) determining the identity of isolated proteins by mass spectroscopy;

wherein the method is performed using an apparatus comprising an autosampler, an affinity-capture apparatus and an ion source.

2. The method of claim 1, wherein the proteins are further cleaved into smaller peptide fragments before, after or during the step of processing the protein samples.

3. The method of claim 2, wherein the proteins are fragmented by enzymatic hydrolysis to produce peptide fragments having carboxy-terminal lysine or arginine residues.

4. The method of claim 3, wherein the proteins are fragmented by treatment with trypsin.

5. The method of claim 1, wherein the proteins are mass-modified with isotopic labels before, after or during the step of processing the protein samples.

6. The method of claim 1, wherein the isolated proteins are further separated by reverse phase chromatography before analysis by mass spectroscopy.

7. The method of claim 1, wherein the isolated proteins are identified from analysis using tandem mass spectroscopy techniques.

8. The method of claim 1, wherein the identity of the isolated proteins are determined by searching molecular weight databases for the molecular weight observed by mass spectroscopy for an isolated protein or peptide fragment thereof.

9. The method of claim 1, further comprising including the step of obtaining amino acid sequence mass spectra for the isolated proteins or peptide fragments, and searching one or more sequence databases for the sequence observed for the identified protein or peptide fragment thereof.

10. The method of claim 1, wherein the moiety of interest is a phosphate group.

11. The method of claim 10, wherein the affinity capture reagent is an immobilized metal affinity chromatography medium, and the step of processing the protein samples includes chemically modifying the side chains of glutamic acid and aspartic acid residues to neutral derivatives.

12. The method of claim 11, wherein the side chains of glutamic acid and aspartic acid residues are modified by alkyl-esterification.

13. The method of claim 1, wherein the protein sample is a mixture of different proteins.

14. The method of claim 13, wherein the protein sample is derived from a biological fluid, or a cell or tissue lysates.

15. The method of claim 1, carried out on multiple different protein samples, wherein the proteins or fragments thereof of each protein sample are isotopically labeled in a manner which permits discrimination of mass spectroscopy data between protein samples.

23. A method for identifying a treatment that modulates a modification of amino acid in a target polypeptide, comprising:

(i) providing a protein sample which has been subjected to a treatment of interest;

(ii) using any one of the methods of claims 1-18, determining the identity of proteins which are differentially modified in the treated protein sample relative to an untreated sample or control sample;

(iii) determining whether the treatment results in a pattern of changes in protein modification, relative to the untreated sample or control sample, which meet a preselected criteria.

24. The method of claim 23, wherein the treatment is effected by a compound.

25. The method of claim 24, wherein the compound is a growth factor, a cytokine, a hormone, or a small chemical molecule.

26. The method of claim 23, wherein the compound is from a chemical library.

27. The method of claim 23, wherein the protein sample is isolated from a cell or tissue subjected to the treatment of interest.

30. A method of conducting a drug discovery business, comprising:

(i) by the method of claim 23, determining the identity of a compound that produces a pattern of changes in protein modification, relative to the untreated sample or control sample, which meet a preselected criteria;

(ii) licensing, to a third party, the rights for further drug development of compounds that alter the level of modification of the target polypeptide.

31. A method of conducting a drug discovery business, comprising:

(i) by the method of claim 1, determining the identity of a protein that is post-translationally modified under conditions of interest;

(ii) identify one or more enzymes which catalyze the post-translational modification of the identified protein under the conditions of interest;

(iii) conduct drug screening assays to identify compounds which inhibit or potentiate the enzymes identified in step (ii) and which modulate the post-translational modification of the identified protein under the conditions of interest.

16. A method for analyzing a phosphoproteome, comprising:

(i) for a protein sample, chemically modify the side chains of glutamic acid and aspartic acid residues to neutral derivatives;

(ii) isolating phosphorylated proteins from the protein sample by immobilized metal affinity chromatography;

(iii) determining the identity of isolated proteins by mass spectroscopy.

17. The method of claim 16, the proteins are cleaved into smaller peptide fragments before, after or during the step of chemically modify the glutamic acid and aspartic acid residues.

18. The method of claim 17, wherein the proteins are fragmented by enzymatic hydrolysis to produce peptide fragments having carboxy-terminal lysine or arginine residues.

19. The method of claim 18, wherein the proteins are fragmented by treatment with trypsin.

20. The method of claim 16, wherein the glutamic acid and aspartic acid residues are modified by alkyl-esterification.

21. The method of claim 16, carried out on multiple different protein samples, and proteins which a differentially phosphorylated between two or more protein samples are identified.

22. The method of claim 16, comprising the further step of generating or adding to a database the identity of proteins which are determined to be phosphorylated.

28. A method of conducting a drug discovery business, comprising:

(i) by the method of claim 20, determining the identity of a compound that produces a pattern of changes in protein modification, relative to the untreated sample or control sample, which meet a preselected criteria;

(ii) conducting therapeutic profiling of the compound identified in step (i), or further analogs thereof, for efficacy and toxicity in animals; and

,

(iii) formulating a pharmaceutical preparation including one or more compounds identified in step (ii) as having an acceptable therapeutic profile.

29. The method of claim 28, including an additional step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.